Director Radiosensitive Cancers
AAA Statement Advanced Accelerator Applications, a Novartis company, is an innovative medicines company focused on the development of products for targeted radioligand therapy and precision radioligand imaging. We are committed to transforming patients' lives by leading innovation in nuclear medicine.
AAA offers professionals the opportunity to face new challenges and pursue a career in a fast growing, technology driven healthcare company. We are passionate about improving patient health by leading innovation in nuclear medicine. We are looking for people who share our commitment to help us achieve this goal. Advanced Accelerator Applications is an Equal Opportunity Employer (EOE). Job Description POSITION PURPOSE:
Global RSC Director will be accountable for contributing to developing overall, cross-functional programs of a priority disease area, especially early in lifecycle - focused on shaping assets with strong commercial potential in line with TA priorities. The role provides direction and functional expertise in a cross-functional RSC team and prioritizes US first with enhanced focus on major markets (e.g., China, Japan, Germany) and ensure close collaboration with Strategy and Early Product, NIBR, GDD and MAP teams.
MAJOR ACCOUNTABILITIES:
1. RSC strategy aligned with Therapeutic Area (TA) strategy
Collaborating to ensure definition and execution of a competitive strategy to establish Novartis as true industry leader within the RSC and maximize patient impact by influencing/ partnering across the disease ecosystem.
* Contribute to defining RSC aspirations, goals, and priorities or across the assets within the RSC, supporting strategic cross-RSC-brand alignments to continuously ensure speaking with one voice to the wider organization
* Support key stakeholders (Global RSC Head, TA Strategy & Early Portfolio Team, IM-US, IMI major markets, MAP team, NIBR & GDD) with early commercial evaluations of assets, particularly at development decision points, bringing deep RSC expertise and commercial acumen; in particular, supporting the assets not reaching Innovative Medicine's strategy, enterprise value criteria or RSC strategy are closed out swiftly
* Contribute to the development of robust forecasts
* Define light-touch (RSC-specific) above-country Health Systems & Policy strategy (objectives, priorities)
2. Asset shaping
Shaping market-relevant assets to become Standard of Care with a focus on US
* Collaborate to develop transformative, US-centric Target Product Profiles (TPPs) that are tangible, provide a clear guidance to the GDD organization on what level of evidence is required.
* Make data-driven, decisive tradeoffs between needs of US and major markets (e.g., CN, JP, DE)
* Bring a deep understanding of customer needs and healthcare ecosystems in priority markets and innovative customer value management approaches to guide development programs
* Co-develop and execute integrated Evidence Plan (IEP) with input into GDD trial design - bringing a credible, aligned commercial perspective to maximize commercialization/patient access potential
3. Integrated early brand strategies
* Collaborate to ensure impactful, actionable early brand strategies until handover to International
* Co-develop Integrated Insights Plan, consolidating and aligning inputs and requirements across functions to achieve deep RSC ecosystem understanding (patient journey, competitive, access landscape, HCS budget impact and cost effectiveness analysis)
* Co-develop early Integrated Product Strategy (IPS) rooted in customer/ market centricity (until handover to International)
* Collaborate to define early medical affairs strategy as part IPS, incl. scientific platform/core claims, disease awareness, medical expert engagement, etc.
* Collaborate to ensure delivery of the early access, reimbursement, and pricing strategies (early Integrated Product Access Strategy) to shape value proposition for HCP / payer / patients / HCS
* Contribute to cross-functionally aligned stakeholder mapping/ prioritization and engagement plan
4. Brand management across the lifecycle
Accountable for maintaining the integrity, consistency, and evolution of each brand across the lifecycle
* Co-develop and maintain an impactful brand identity, positioning, aligning across commercial, medical requirements for global brand consistency
* Co-develop and maintain a pricing strategy framework/ link for global price cross-referencing
* Collectively define and coordinate lifecycle management (LCM) strategy (incl. indications strategy/ sequencing, formulations, connected devices, combinations, follow-on assets)
5. Collaboration
Successfully working within a cross-functional RSC team to achieve goals
* Work in a diverse, high performance, cross-functionally matrixed team including identifying and integrating expertise and inputs required from other teams to ensure successful delivery (e.g., MAP)
* Bring in functional expertise in cross-functional areas (commercial, medical, market access, development, finance) to ensure appropriate focus dedicated to assets
* Ensure appropriate compliance against company policies and procedures Commitment to Diversity & Inclusion: Novartis is committed to building an outstanding, inclusive work environment and diverse teams representative of the patients and communities we serve. Minimum requirements Mandatory:
* At least 10 years senior level pharmaceutical commercial, marketing, medical, access or R&D experience successfully driving growth of multiple brands
* Experience of strategy development and asset shaping early in lifecycle (from any functional perspective - marketing, new products, access, medical, clinical, R&D)
* Deep RSC knowledge (or track record to acquire required RSC expertise effectively and rapidly)
* Prior experience in launching specialty brand(s) in major market(s) (US, CN, JP, EU5, AUS, CAN)
Preferred:
* Significant (3+ years) and recent (post 2015) local US experience preferred; Local US experience includes working in the US market with the local US customers, US health care systems/ systems of care, US payors/ accounts, etc.), driving US market strategy
* Significant (3+ years) and recent (post 2015) experience in above country (regional or global) role
* RLT experience preferred
* Minimum 3 years Oncology experience preferred
* Established relationships with relevant Global KOLs
* Proven experience credibly interacting and influencing stakeholders in research and drug development
* Track record of successfully working within matrix of Commercial, Medical Affairs, and Market Access, as well as breaking down functional silos and managing complex trade-offs
#RLT
Job locations: Switzerland or US Business Unit ADVANCED ACCELERATOR APPLICATIONS Work Location East Hanover, NJ Company/Legal Entity AAA USA Inc.
|
Novartis Group Companies
March 14, 2023